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Objective: Oral health conditions have a signiﬁcant relationship with diabetes mellitus (DM) as well as dys-
lipidemia. In this study, we investigated the levels of apolipoprotein B (apoB) and oxidized low-density lipopro-
tein (oxLDL) in the gingival crevicular ﬂuid (GCF) from patients with DM.
Methods:GCF and blood samples from 18 DMpatients and 18 healthy subjects were examined. GCFwas col-
lected with paper points without inﬂicting any harm. The apoB and oxLDL levels were measured by sandwich
ELISA assays.
Results: The number of teeth with a deep probing pocket depth and the number of teeth with bleeding on
probing, two typical periodontal parameters, correlated with the DM parameters, such as hemoglobin A1c. The
GCF volume and the concentrations of protein, apoB and oxLDL in GCF were signiﬁcantly higher in the DM pa-
tients than in the healthy subjects. In particular, the apoB concentration in GCF was increased 6-fold in the DM
patients. The GCF apoB concentration correlated well with the DM parameters in plasma.
Conclusion: GCF could be a clinical source for examining not only the oral status of patients, but also certain
systemic conditions.© 2013 The Authors. The Canadian Society of Clinical Chemists. Published by Elsevier Inc.
Open access under CC BY-NC-SA license.Introduction
Gingival crevicular ﬂuid (GCF) is the physiological exudate present
in the crevice between a tooth and the surrounding gingival tissues. Al-
though the source of GCFhas not been fully established [1], GCF contains
various plasma proteins and components derived from local gingival
cells [2,3]. As periodontal disease progresses, the volume of GCF in-
creases and inﬂammatory cytokines appear in theGCF. GCF can be easilys index; BOP, bleeding on prob-
nzyme-linked immunosorbent
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istry, Department of Molecular
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Clinical Chemists. Published by Elsevand non-invasively collected using dental paper points, so that it has
been studied as a potential target for clinical examinations [4].
It is becoming increasingly evident that oral health conditions have
relevance to systemic diseases. In particular, periodontal disease is con-
sidered to be one of the complications of diabetes mellitus (DM) [5].
Periodontal disease is caused by a chronic infection in which the peri-
odontal tissues are eroded by both the pathogens present in the peri-
odontal pockets and the inﬂammatory responses to them, such that
the alveolar bone is absorbed and ultimately a loss of teeth occurs [6].
It is well established that patients with DM have at least a 2-fold in-
crease in the risk of periodontal disease compared with non-diabetic
subjects [7]. Furthermore, unlike most of the other diabetic complica-
tions, periodontal disease and DM have a reciprocal interaction [8],
namely, periodontal disease is a risk factor for DM, while DM patients
are more susceptible to periodontal disease.
It is well known that patients with DM often exhibit an increased
risk for cardiovascular disease due to some combination of hypergly-
cemia, hyperlipidemia, obesity and hypertension in a given patient
[9,10]. Epidemiological studies have reported an association be-
tween periodontal disease and dyslipidemic conditions [11]. The
presence of Porphyromonas gingivalis, one of the major pathogenic
bacteria of periodontal disease, has been suggested in atherosclerot-
ic plaques, using PCR analysis to detect the speciﬁc DNA fragments
[12]. Extensive treatment of patients with periodontal disease isier Inc. Open access under CC BY-NC-SA license.
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ever, whether periodontal disease is a direct cause of atherosclerotic
vascular diseases has yet to be proven conclusively [14].
Based on these backgrounds, we thought that GCF is potentially a
good source to investigate the relationship between systemic diseases
and oral conditions. Previously we showed that apolipoprotein B
(apoB) is present in GCF and that oxidized low-density lipoprotein
(oxLDL) is enriched even in the GCF from healthy subjects [15]. In this
study, we examined the amounts of apoB and oxLDL in the GCF collect-
ed from DM patients and healthy subjects. The GCF was sampled from
the gingival tissues unafﬂicted with periodontal disease to investigate
whether GCF changes under the conditions of a systemic disease such
as DM.
Materials and methods
Patients
The subjects enrolled in this study were fully informed of the protocol
of this study andwritten informed consent was obtained according to the
Helsinki Declaration. The experimental protocol for this study was ap-
proved by the ethical committee of Showa University. A total of 40 sub-
jects (22 patients and 18 control subjects) were recruited from July 2011
to July 2012. Those patients who had been diagnosed as having type 1
or 2 DM (HbA1c N 7.8%; NGSP values) for more than one year before
the study were hospitalized for approximately one week as an inpatient
education program for diabetes. The smoking history was checked
according to a standardized questionnaire. Subjects requiring periodontal
surgery were excluded. Additional exclusion criteria included a history of
periodontal therapy, the current use of antibiotics or anti-inﬂammatory
drugs within the previous 3 months, pregnancy or lactation, and fewer
than 20 teeth. Ultimately, 18 patients with DM hospitalized in Showa
University Hospital and 18 healthy subjects were examined. The basic
characteristics, including age, gender, and duration of DM, are summa-
rized in Table 1. Among the 18 DM patients, only one patient was type
1. Two GCF samples at the sites of two different teeth and a venous
blood sample were collected from each participant.
The periodontal status and the parameters for hyperglycemia and
hyperlipidemia
All of the DM patients and healthy subjects received a dental exam-
ination. For examination of periodontal status the probing pocket depth
(PPD) and bleeding on probing (BOP) at the deepest site of each tooth
were recorded. The degree of periodontal disease is evaluated by the
periodontal scores, which are the average PPD of all the teeth, the per-
centage of pocket sites with PPD more than 4 mm and the percentage
of BOP-positive sites. Dental plaque was collected from the two teethTable 1
Clinical characteristics of the subjects.
Non-diabetes
n = 18
Diabetes
n = 18
p-Value
Gender (male/female) 13/5 12/6 0.7
Age (years) 50.2 ± 6.4 59.1 ± 15.1 0.029⁎
BMI (kg/m2) 22.1 ± 3.4 24.2 ± 5.4 0.159
HbA1c (NGSP %) 5.4 ± 0.5 11.4 ± 2.5 0.0001⁎
Glycoalbumin (GA %) 14.1 ± 2.0 30.3 ± 7.9 0.0001⁎
Fasting blood glucose (mg/dL) 88.3 ± 25.2 202.8 ± 63.4 0.0001⁎
Duration of diabetes (month) 0 109.5 ± 105.5
Smoker/non-smoker 1/17 4/14 0.14
LDL-C (mg/dL) 120.1 ± 23.9 145.7 ± 52.3 0.075
HDL-C (mg/dL) 57.7 ± 16.4 43.9 ± 8.1 0.004⁎
TG (mg/dL) 133.2 ± 68.4 187.7 ± 72.6 0.027⁎
MDA-LDL (U/L) 99.6 ± 41.7 131.2 ± 64.5 0.145
Values are given as mean ± SD.
⁎ p-Value for comparisons between the non-DM andDM subjects (Welch test) was b0.05.used for GCF sampling. Total bacterial counts were calculated by real-
time PCR using DNA probes speciﬁc for 5 major bacteria causing peri-
odontal disease at the BML Co. (Tokyo, Japan).
Venous blood (26 mL) was drawn from a brachial vein using a
collecting tube, and 21 mL out of the 26 mL blood was used tomeasure
the following parameters: HbA1c was measured using a latex coagula-
tion method, while glycoalbumin (GA), fasting blood glucose, triglycer-
ide (TG), LDL-cholesterol (LDL-C), and HDL-cholesterol (HDL-C) were
measured using enzymatic methods, and malondialdehyde-modiﬁed
LDL (MDA-LDL) was measured using an ELISA procedure, all of which
were performed at the BML Co. The rest of the sample was immediately
centrifuged at 15,000 ×g for 10 min to separate the plasma for the de-
termination of the apoB and oxLDL concentrations. The subjects' diet
was not modiﬁed in any way prior to blood collection. The chylomicron
(CM), very low-density lipoprotein (VLDL) and LDL fractions were sep-
arated using sequential ultracentrifugation, as described previously
[16]. Protein concentrations were determined using BCA protein assay
reagent with BSA as the standard. The CM, VLDL and LDL samples
were stored at 4 °C until analysis.
Collection of the GCF samples
GCF samples were collected using a method described previously
[15]. Brieﬂy, two buccal maxillary anterior teeth with shallow pockets
were selected in each subject. When the average PPD of the two sites
was more than 4 mm, the subject was dropped from this study to min-
imize the effects of local gingival inﬂammation on GCF. The site of GCF
collection was isolated with cotton wool rolls, and saliva was gently re-
moved from the adjacent tooth surface and gingiva using a blower
brush. Two standard paper points (DENTSPLY International Inc., York,
PA, USA) were gently inserted in the buccal gingival crevice for 1 min
and then transferred into 100 μL of ice-cold sterilized phosphate-
buffered saline (PBS) containing protease inhibitor cocktail (Sigma-Al-
drich, product no. P2714; ﬁnal 5% v/v). After 5 min, the same procedure
was repeated with new paper points, and the volume of GCF was mea-
sured using a pre-calibrated Periotron 8000 (ProFlow Inc., New York,
NY, USA). GCF samples were stored at 4 °C until use. In total, 35 GCF
samples for each group were examined, since we were able to recover
only one GCF sample from one DM patient and one control subject.
Determination of the apoB and oxLDL concentrations
The concentrations of oxLDL in the GCF and plasma samples were
measured using a sandwich ELISA protocol [15,16] that was modiﬁed
slightly to improve the sensitivity. Brieﬂy, 96-well microtiter plates
(Costar, product no. 3369; NY, USA) were incubated with 100 μL of
the anti-oxidized phospholipid mAb DLH3 (diluted to 10 μg/mL in
PBS) [17] at RT with shaking for 2 h and then at 4 °C for four days.
After blocking the plates with TBS containing 2% BSA, 100 μL of samples
was incubated in the wells at 37 °C for 2 h and then at 4 °C overnight.
The plates were subsequently washed four times with 340 μL of TBS
containing 0.1% Tween-20 (TBS-T). The plates were incubated with a
sheep anti-human apoB pAb (Binding Site Inc., Birmingham, UK) at RT
with shaking for 2 h, then washed four times with TBS-T. A biotin-
conjugated donkey anti-sheep pAb (Millipore; 1:50,000 diluted in TBS
containing 1% skimmed milk) was added to the wells and incubated at
37 °C for 1 h. After washing four times with TBS-T, a complex of
streptavidin and biotinylated alkaline phosphatase (Dako Cytomation;
1:100 diluted in Tris–HCl, pH 7.8)was added to thewells and incubated
at 37 °C for 1 h. The plates werewashed four timeswith TBS-T and then
oncewith 100 μL of 50 mMTris–HCl, pH 8.8. The plateswere incubated
with 100 μL per well of p-nitrophenyl phosphate solution for 1 h at
37 °C. Copper induced-oxidized human LDL was used as the standard.
Under the present assay conditions 0.05 ng protein/well of oxLDL was
detected, which is approximately one order more sensitive than the
original procedures. The measurement of apoB was carried out by
Table 3
Correlations between the periodontal parameters and the hyperglycemic and
hyperlipidemic parameters in plasma.
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LDL, VLDL and CM fractions were combined to estimate the total apoB
plasma concentration.HbA1c
(NGSP)
GA Fasting blood
glucose
TG LDL-C MDA-LDL
Percentage of
diseased site
(PPD ≥ 4 mm)
.518⁎ .572⁎ .461⁎ .274⁎⁎ .201 .244⁎⁎
Percentage of
bleeding sites
(BOP)
.367⁎⁎ .243⁎⁎ .298⁎⁎ .176 .024 .108
Total bacterial count .223 .220 .246⁎⁎ .024 .201 .040
⁎ Correlations signiﬁcant at p b 0.01 level by Pearson's correlation test.Statistical analysis
The results are presented as the means ± standard deviation. For
the statistical analysis, Welch t-test and Pearson's correlation were car-
ried out using the Statistical Package for the Social Sciences (version
18.0, SPSS Inc., Chicago, IL, USA) software. A p value b 0.05 was taken
to be signiﬁcant.⁎⁎ Correlations signiﬁcant at p b 0.05 level by Pearson's correlation test.Results
Basic characterization of the DM patients
Table 1 shows the characteristics of the DM patients (n = 18) and
non-DM subjects (n = 18) examined in this study. The levels of
HbA1c, GA and fasting blood glucose clearly indicated poor glycemic
control in the DM patients. The patients had been diagnosed with DM
for 109.5 months on average (3–360 months). Body mass index
(BMI), the smoker/non-smoker ratio, LDL-C and MDA-LDL were all
slightly higher in the DM patients, but not signiﬁcantly. HDL-C was
lower and TG was higher in the DM patients, suggesting an association
of lipid metabolism with DM.Periodontal parameters of the DM patients
Periodontal disease is reportedly the sixth most common complica-
tion of DM. As periodontal disease progresses, the connective tissue sur-
rounding the teeth is destructed and the alveolar bone absorbed, the
probing pocket depth (PPD) correspondingly increases. In terms of the
clinical criteria, PPD ≥ 4 mm is deﬁned as periodontitis. GCF samples
were collected from two non-diseased teeth per subject; the average
PPDs of the GCF collection sites were less than 3 mm(Table 2). Bleeding
on probing (BOP) indicates the disease activity at the probing site. The
percentages of teeth with deep PPD or BOP and the number of residual
teeth were signiﬁcantly higher in the DM patients than non-DM sub-
jects (Table 2). The total bacterial counts for the collection sites were
not signiﬁcantly different between the two groups.
As shown in Table 3, the periodontal scores correlate with the DM
parameters. BOP correlates positively with HbA1c, GA and fasting
blood glucose. Even stronger correlations are observed between the
percentage of deep PPD and the DM parameters. The percentage of
deep PPD also correlates with TG and MDA-LDL.Table 2
Periodontal characteristics of the subjects.
Non-diabetes
n = 18
Diabetes
n = 18
p-Value
Full-mouth measurements
Probing pocket depth (PPD)
Percentage of diseased sites (PPD ≥ 4 mm) 5.1 ± 7.8 24.5 ± 15.4 0.0001⁎
Bleeding on probing (BOP)
Percentage of bleeding sites 3.2 ± 3.9 15.5 ± 11.3 0.001⁎
Number of residual teeth 27.7 ± 2.6 24.2 ± 3.5 0.0002⁎
Collection sites
Average PPD of collection sites (mm) 2.1 ± 0.3 2.8 ± 0.7 0.0001⁎
Total bacterial count (104 copy) 1.1 ± 1.3 2.1 ± 2.3 0.2
Values are given as mean ± SD.
Full-mouth measurements of probing pocket depth (PPD) and bleeding on probing (BOP)
were recorded using a manual probe.
⁎ p-Value for comparisons between the non-DM andDM subjects (Welch test) was b0.05.The GCF from DM patients and healthy subjects shows different
characteristics
GCF is easily and non-invasively collected using dental paper points.
The volume and protein concentration of the collected GCF samples
were signiﬁcantly higher in the DM patients than in the non-DM sub-
jects (p b 0.01) (Fig. 1a, b). In addition, attentionwas focused on certain
components of GCF, since we had identiﬁed apoB and oxLDL in GCF in a
previous study [15]. The apoB and oxLDL concentrations in GCF, as de-
termined by sandwich ELISA procedures, were signiﬁcantly higher in
the DM than non-DM subjects (p b 0.01 and p b 0.05, respectively)
(Fig. 1c, d). The GCF apoB concentration was signiﬁcantly higher in
the DM patients even when the data was adjusted for age (DM
653.2 ± 939.6 ng/mL vs. non-DM 82.9 ± 42.7 ng/mL; p b 0.01).
Table 4 shows the relationship between GCF and the plasma param-
eters. The GCF volume positively correlated with the DM parameters.
The GCF protein concentration also positively correlated with GA and
fasting blood glucose. However, the GCF volume and GCF protein con-
centration did not correlate with the hyperlipidemic parameters of TG,
LDL or MDA-LDL. We found that the apoB in GCF showed a good corre-
lation with the DM parameters, and it correlated signiﬁcantly with TG,
LDL and MDA-LDL, respectively. On the other hand, the apoB and
oxLDL in GCF did not display any correlation with either apoB or
oxLDL in plasma.
Fig. 2 shows the receiver operating characteristic (ROC) analysis of
the apoB and oxLDL concentrations in GCF conducted for the purpose
of DM prediction. The curve for the apoB concentration in GCF runs
very close to the upper left corner, and the area under the curve in
GCF apoB was 0.90, which is statistically signiﬁcant (p b 0.01). Given
that the GCF samples were collected from non-diseased sites, this data
indicates that 80% of the DM patients could be predicted speciﬁcally
by apoB in the GCF collected from healthy teeth without any false pos-
itives under an appropriate threshold. An effective cut-off value was
138 ng/mL, bywhich the data shows 86% sensitivity and 94% speciﬁcity.
The curve for the oxLDL concentration in GCF partly overlaps the diago-
nal line, indicating that it is not suitable for the prediction of DM.
Discussion
GCF is the physiological exudate in the crevices between teeth and
the surrounding gingiva. Since GCF can be collected easily without any
substantial harm, it is potentially useful for clinical examinations. We
found previously that apoB and oxLDL are present in the GCF taken
from subjects who were healthy both periodontally and systemically
[15]. In the current study, we found the apoB concentrations to be re-
markably higher in the GCF from the DM patients than the healthy sub-
jects. In particular, the GCF apoB concentration exhibited a good
correlation with DM as well as the hyperlipidemic parameters.
It is now recognized that periodontal disease is a complication of DM
[5,7]. The DM patients examined in this study showed signiﬁcant in-
creases in their periodontal scores as well as the DM parameters. To
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Fig. 1. The characteristics of the GCF samples from the DMpatients and healthy subjects. The GCF samples were collected from two sites per subject. (a) GCF volumewasmeasured using a
pre-calibratedPeriotron8000. (b) The protein concentration in theGCF samples (recovered in100 μL PBS)wasmeasuredusing a BCAassay, then theoriginal GCFprotein concentrationwas
estimated using the data on the GCF volume. The amounts of apoB (c) and oxLDL (d) in the GCF samples were determined by sandwich ELISA. Results are presented as the means ± S.D.
Statistical analysis was performed using the Welch test. *p b 0.01, **p b 0.05.
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from non-diseased sites, since GCF from a diseased site could be a reﬂec-
tion of the inﬂammatory reactions in the gingiva as well as systemic
conditions. In addition, although the volume of GCF increaseswhen peri-
odontal disease progresses, collecting GCF from diseased sites eroded by
chronic inﬂammation is often accompanied by bleeding.
Our data show that the GCF volume and protein and oxLDL concen-
trationswere signiﬁcantly higher in the DMpatients than in the healthy
subjects. It cannot be denied that a local inﬂammatory response is also
involved in the increase in GCF and the change of the components in
GCF. We conjecture that the increased protein concentration and
oxLDL level are not caused solely by local inﬂammatory responses, but
rather, there must also be an effect of the systemic disease. The gingival
capillaries are enriched in the tissue attached to teeth compared to the
intraoral surface of the gingiva [18]. The volume and components of
GCFmay thus be strongly inﬂuenced by endothelial function in the cap-
illaries. Some of pro-inﬂammatory cytokines, such as IL-1β and IL-8, are
increased in the GCF from DM patients that increase vascular perme-
ability [19,20]. It is well known that the vessels inmany different tissues
are damaged in DM patients, and increased extravasation of leukocytes
and macromolecules under hyperglycemic conditions has been report-
ed for gingival tissue [21].
ApoB and oxLDL in GCF showed no correlation with either apoB or
oxLDL in plasma, suggesting that the permeation of apoB into GCF is in-
dependent of the plasma apoB concentration. Also, the oxLDL data con-
ﬁrms our previous report that the oxLDL/apoB ratio in GCF was 17-fold
higher than that in plasma [15], supporting the notion that oxLDL inGCF
does not simply originate from plasma. It is noteworthy that only 3 out
of 18 DM patients in this study had history of diseases closely related to
atherosclerosis, i.e. cardiovascular diseases, cerebral infarction, and ath-
erosclerosis obliterans.Table 4
Correlations between the GCF parameters and the hyperglycemia and hyperlipidemia paramet
HbA1c (NGSP) GA Fasting blood glucose
GCF-volume .462⁎ .509⁎ .505⁎
GCF-protein .183 .314⁎⁎ .334⁎⁎
GCF-apoB .333⁎ .398⁎ .459⁎
GCF-oxLDL .265⁎⁎ .303⁎⁎ .209
⁎ Correlations signiﬁcant at p b 0.01 level by Pearson's correlation test.
⁎⁎ Correlations signiﬁcant at p b 0.05 level by Pearson's correlation test.In addition, the apoB concentration in the DM patient GCF was 6-
times higher than that in healthy subjects, while the GCF protein con-
centration in the DM patients was only 1.6-times higher than that in
healthy subjects. No GCF sample from the healthy subjects had an
apoB concentration higher than 250 ng/mL, while the plasma apoB con-
centration is estimated to be 5 μg/mL when it is diluted in PBS in the
same way as GCF samples. It is thus suggested that the release of an ex-
tremely large protein-like apoB from plasma into GCF is tightly regulat-
ed. LDL can be transferred from the vessel lumen to the tissue area
beyond the endothelial cell layer. Receptor-mediated transcytosis of
LDLwas demonstrated in endothelial cells from the aorta and brain cap-
illaries in culture [22,23], and the in vivo evidence for the extravasation
of LDLwas also reported [24,25]. It is possible that LDL-receptor function
in the gingival capillaries might be affected under DM conditions and
thus the apoB concentration increases in GCF. This might also explain
why the GCF apoB concentration correlates with the hyperlipidemic pa-
rameters in addition to the DM parameters. Further study is certainly
needed to clarify the cause of the selective increase of apoB in GCF.
The ROC analysis of the GCF apoB concentration suggests that it may
be a sensitive marker for hyperglycemic conditions, since the GCF apoB
concentration is very stable in healthy people. GCF could be a clinical
source to study some systemic conditions, not just the oral status. For
example, if corroborated by further study, GCF may provide a way to
contribute to a better cooperative treatment of patients with DM via
both metabolic control and oral care.
The limitations of this study include the fact that the DM patients ex-
aminedwere under poor hyperglycemic control. We recruited the hospi-
talized patients enrolled in an education program so it would be possible
to carefully examine the oral conditions of the DM patients during the
stay in the hospital. Future study should examine a cohort with a larger
number of patients with intermediate as well as severe hyperglycemia.ers in plasma.
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Fig. 2. Receiver operating characteristic (ROC) curves of the apoB and oxLDL concentrations
in GCF for the prediction of DM. The ROC curves plot the sensitivity vs. 1-speciﬁcity by a
gradual change in the cutoff value.
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